Sorrento Therapeutics, Inc. - Product Pipeline Review

Global Markets Direct’s, ‘Sorrento Therapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the Sorrento Therapeutics, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sorrento Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Sorrento Therapeutics, Inc.

The report provides overview of Sorrento Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Sorrento Therapeutics, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Sorrento Therapeutics, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Sorrento Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Sorrento Therapeutics, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Sorrento Therapeutics, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Sorrento Therapeutics, Inc. Snapshot 7

Sorrento Therapeutics, Inc. Overview 7 ...

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Sorrento Therapeutics, Inc. Snapshot 7

Sorrento Therapeutics, Inc. Overview 7

Key Information 7

Key Facts 7

Sorrento Therapeutics, Inc. - Research and Development Overview 8

Key Therapeutic Areas 8

Sorrento Therapeutics, Inc. - Pipeline Review 12

Pipeline Products by Stage of Development 12

Pipeline Products - Monotherapy 13

Pipeline Products - Partnered Products 14

Partnered Products/Combination Treatment Modalities 15

Sorrento Therapeutics, Inc. - Pipeline Products Glance 16

Sorrento Therapeutics, Inc. - Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Sorrento Therapeutics, Inc. - Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Discovery Products/Combination Treatment Modalities 20

Sorrento Therapeutics, Inc. - Drug Profiles 21

Cellular Immunotherapy to Target CEA for Oncology 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Cellular Immunotherapy to Target PD-L1 for Oncology 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Cellular Immunotherapy to Target PSMA for Prostate Cancer 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

BA-0702 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

CBA-0710 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Cellular Immunotherapy to Target c-KIT for Solid Tumors 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Cellular Immunotherapy to Target CD123 for Acute Myeloid Leukemia 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Cellular Immunotherapy to Target CD33 for Acute Myeloid Leukemia 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Cellular Immunotherapy to Target GD3 for Solid Tumors 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Cellular Immunotherapy to Target HER-2 for Glioblastoma 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Cellular Immunotherapy to Target HER2 for Oncology 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Cellular Immunotherapy to Target IL13R Alpha2 for Glioblastoma Multiforme 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Cellular Immunotherapy to Target MUC-16 for Ovarian Cancer 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Cellular Immunotherapy to Target ROR1 for Solid Tumor 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Monoclonal Antibody to Inhibit CD47 for Oncology 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Monoclonal Antibody to Inhibit Ghrelin for Obesity 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Monoclonal Antibody to Target EGFR and Inhibit PD-L1 for Oncology 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

rituximab biosimilar 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Small Molecules to Inhibit c-Myc for Solid Tumors and Hematological Malignancies 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

STI-600 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

STIA-0168 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

STIA-1011 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

STIA-1012 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

STIA-1014 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

STIA-1015 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

STIA-1110 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

STIB-0201 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

STIC-0205 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

STID-0602 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

BC-001 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

clostridium difficile vaccine 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Monoclonal Antibodies for Clostridium difficile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Monoclonal Antibodies for Hepatitis C 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Monoclonal Antibodies to Inhibit WISP1 for Idiopathic Pulmonary Fibrosis 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

STI-001 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Sorrento Therapeutics, Inc. - Pipeline Analysis 57

Sorrento Therapeutics, Inc. - Pipeline Products by Target 57

Sorrento Therapeutics, Inc. - Pipeline Products by Route of Administration 59

Sorrento Therapeutics, Inc. - Pipeline Products by Molecule Type 60

Sorrento Therapeutics, Inc. - Pipeline Products by Mechanism of Action 61

Sorrento Therapeutics, Inc. - Recent Pipeline Updates 63

Sorrento Therapeutics, Inc. - Dormant Projects 64

Sorrento Therapeutics, Inc. - Discontinued Pipeline Products 66

Discontinued Pipeline Product Profiles 66

paclitaxel 66

Sorrento Therapeutics, Inc. - Locations And Subsidiaries 67

Head Office 67

Other Locations & Subsidiaries 67

Appendix 68

Methodology 68

Coverage 68

Secondary Research 68

Primary Research 68

Expert Panel Validation 68

Contact Us 68

Disclaimer 69

List of Tables

List of Tables

Sorrento Therapeutics, Inc., Key Information 7

Sorrento Therapeutics, Inc., Key Facts 7

Sorrento Therapeutics, Inc. - Pipeline by Indication, 2016 9

Sorrento ...

List of Tables

Sorrento Therapeutics, Inc., Key Information 7

Sorrento Therapeutics, Inc., Key Facts 7

Sorrento Therapeutics, Inc. - Pipeline by Indication, 2016 9

Sorrento Therapeutics, Inc. - Pipeline by Stage of Development, 2016 12

Sorrento Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016 13

Sorrento Therapeutics, Inc. - Partnered Products in Pipeline, 2016 14

Sorrento Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 15

Sorrento Therapeutics, Inc. - Phase II, 2016 16

Sorrento Therapeutics, Inc. - Phase I, 2016 17

Sorrento Therapeutics, Inc. - Preclinical, 2016 18

Sorrento Therapeutics, Inc. - Discovery, 2016 20

Sorrento Therapeutics, Inc. - Pipeline by Target, 2016 57

Sorrento Therapeutics, Inc. - Pipeline by Route of Administration, 2016 59

Sorrento Therapeutics, Inc. - Pipeline by Molecule Type, 2016 60

Sorrento Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016 61

Sorrento Therapeutics, Inc. - Recent Pipeline Updates, 2016 63

Sorrento Therapeutics, Inc. - Dormant Developmental Projects,2016 64

Sorrento Therapeutics, Inc. - Discontinued Pipeline Products, 2016 66

Sorrento Therapeutics, Inc., Subsidiaries 67

List of Figures

List of Figures

Sorrento Therapeutics, Inc. - Pipeline by Top 10 Indication, 2016 9

Sorrento Therapeutics, Inc. - Pipeline by Stage of Development, 2016 12 ...

List of Figures

Sorrento Therapeutics, Inc. - Pipeline by Top 10 Indication, 2016 9

Sorrento Therapeutics, Inc. - Pipeline by Stage of Development, 2016 12

Sorrento Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016 13

Sorrento Therapeutics, Inc. - Partnered Products in Pipeline, 2016 14

Sorrento Therapeutics, Inc. - Pipeline by Top 10 Target, 2016 57

Sorrento Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2016 60

Sorrento Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 61

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports